Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer
– Funds will be used to establish clinical proof of concept for Artiva’s CAR-NK and universal NK cell therapies– Artiva has exclusive access to a proprietary large-scale NK cell manufacturing platform and infrastructure– First clinical study planned for later this year followed by two additional clinical programs June 26, 2020 12:00 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–Artiva […]
Checkmate Pharmaceuticals Secures $85 Million in Series C Financing
Funding Supports Further Clinical Development of Checkmate Pharmaceuticals TLR9 Agonist, CMP-001, in Melanoma and other Oncology Indications June 10, 2020 07:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Checkmate Pharmaceuticals (Checkmate), a clinical stage biotechnology company focused on improving patients’ lives with its novel approach to cancer immunotherapy, announced that it has completed an $85 million […]
Roche makes a platform play, betting $190M in cash on Arrakis’ long-haul plans to drug RNA
Every biotech startup sets out at its own idea of a deliberate pace. And they often fall into 2 separate styles. There are the sprinters who leap straight into a slate of deals, looking to align themselves with the kind of blue chip partners that help validate their place in the development pipeline.
All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study
All AKR-001 dose groups met the primary endpoint, with statistically significant absolute reductions in liver fat of 12-14%All AKR-001 dose groups met the secondary endpoint of relative reduction in liver fat, with the 50mg and 70mg dose groups achieving >70% relative reductionsBlinded tolerability profile appears consistent with results from previous clinical trials evaluating AKR-001 in […]
ALX Oncology Announces Closing of $105 Million Series C Financing
Proceeds to Advance and Expand ALX148 Clinical Program DUBLIN, Ireland and BURLINGAME, Calif. – February 12, 2020 – ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the closing of a $105 million Series C equity financing. Vivo Capital was the lead investor with other new investors including funds managed […]
NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic
January 08, 2020 03:00 AM Eastern Standard Time NAARDEN, The Netherlands–(BUSINESS WIRE)–NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, today announced the closing of a US $40 million (€36 million) Series B financing round. NST welcomes […]
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced positive results from the Phase 3 PEGASUS study evaluating pegcetacoplan (APL-2) in adults with paroxysmal nocturnal hemoglobinuria (PNH). Top-line data show that pegcetacoplan met the study’s primary efficacy endpoint, demonstrating superiority to eculizumab […]
